Apellis Discloses Multiple Shareholder Lawsuits Challenging Biogen Merger
APLS has more than doubled off its 52-week low of $16.1.
Summary
Apellis Pharmaceuticals has filed an amendment to its tender offer statement, disclosing three new lawsuits and 13 demand letters from shareholders challenging the proposed acquisition by Biogen Inc. The lawsuits allege material misrepresentations and omissions in merger disclosures and seek to prevent or rescind the deal.
Key Events · M&A and Partnerships · APLS
-
New Shareholder Lawsuits Filed
Three new lawsuits have been filed by purported stockholders (Harris, Clark, Schwartz) against Apellis, its directors, Biogen, and Aspen Purchaser Sub, Inc. The lawsuits allege negligent misrepresentation and concealment, and negligence, claiming the Schedule 14D-9 and Schedule TO misrepresent and/or omit material information.
-
Injunctive Relief Sought
The lawsuits seek, among other things, injunctive relief to prevent the consummation of the proposed transactions until alleged omitted material information has been disclosed, or rescission of the transactions if consummated.
-
Additional Demand Letters Received
As of May 6, 2026, Apellis has received 13 demand letters from purported stockholders, generally alleging disclosure deficiencies related to the proposed transactions.
-
Company Denies Allegations
The defendants believe that the allegations and claims asserted in the complaints and demand letters are without merit and that the disclosures comply fully with applicable law.
Analysis · APLS · Life Sciences
This amendment to the tender offer statement reveals significant legal challenges to the proposed acquisition by Biogen Inc. The disclosure of three new shareholder lawsuits and 13 demand letters, all alleging material misrepresentations and omissions in the merger disclosures, introduces considerable risk and uncertainty to the deal. These lawsuits seek injunctive relief to prevent the consummation of the merger or rescission if completed, which could delay or even jeopardize the transaction. While Apellis believes the claims are without merit, such litigation can create investor apprehension, especially as the stock is currently trading near its 52-week high, close to the tender offer price.
At the time of this filing, APLS was trading at $41.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.3B. The 52-week trading range was $16.10 to $41.14. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.